Indication
- Indicated in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
- Indicated in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC.
- Indicated as a single agent, for the treatment of advanced RCC after failure of one prior systemic therapy.
Last updated on 12/13/2022